Rosetta Green Closes Israeli IPO, Raising $6M to Advance microRNA Programs

While it didn't need necessarily need the money from the IPO to continue operations, the money raised will allow Rosetta Green to “ramp up more quickly and accelerate the work they are doing,” a Rosetta Genomics official said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.